搜尋結果
Will Roche Stock Rebound To Its 2022 Highs Of $50?
Forbes· 4 日前In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over this ...
Will Elevidys Approval Make Sarepta Stock An Acquisition Target?
Forbes· 3 日前The stock price of Sarepta Therapeutics, a biotech company focused on the discovery ...